A purification method for recombinant human type III collagen

By using a two-step chromatography method, the specific sequence characteristics and charge distribution of recombinant human type III collagen are utilized to achieve efficient and low-cost purification, solving the problems of complex purification and low purity in existing technologies, and making it suitable for large-scale industrial production.

CN122145608BActive Publication Date: 2026-11-17YANTAI ZHENGHAI BIO TECH
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202610359924.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2026-03-23
Publication Date
2026-11-17
Estimated Expiration
2046-03-23

AI Technical Summary

Technical Problem

Existing methods for purifying recombinant collagen are complex, costly, and difficult to obtain high-purity products, which limits its application in the fields of medical devices and pharmaceuticals.

Method used

A two-step chromatography method was adopted. First, primary purification was performed by utilizing the natural affinity of recombinant human type III collagen with heparin affinity chromatography medium. Then, advanced purification was performed by cation chromatography. By combining its specific charge distribution and isoelectric point characteristics, efficient separation and purification were achieved.

Benefits of technology

The process has been simplified, the purity has been significantly improved, the endotoxin content is less than 5 EU/mg, which meets the Class III medical device injection grade raw material standard, reduces production costs, and is suitable for large-scale industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122145608B_ABST
    Figure CN122145608B_ABST
Patent Text Reader

Abstract

This invention discloses a purification method for recombinant human type III collagen, the amino acid sequence of which is shown in SEQ ID NO:1. The method includes: (1) obtaining a fermentation supernatant containing collagen; (2) loading the supernatant onto a heparin affinity chromatography column and eluting with an elution buffer containing NaCl; (3) diluting the primary eluted protein and loading it onto a cation exchange chromatography column and eluting with an elution buffer containing NaCl; and (4) ultrafiltration dialysis to obtain a collagen stock solution. This invention utilizes the natural affinity and charge characteristics of the collagen with heparin to achieve efficient purification. The purity of the obtained stock solution is ≥99%, and the endotoxin content is ≤5 EU / mg, which meets the standards for Class III medical devices. The method is simple, low-cost, and easy to scale up, making it suitable for industrial production.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of bioengineering technology, specifically relating to a purification method for recombinant human type III collagen. Background Technology

[0002] In recent years, the domestic collagen market has experienced rapid growth, becoming the "third force" in the medical aesthetics industry, alongside hyaluronic acid and botulinum toxin. Type III collagen is an important member of the collagen family, mainly found in tissues such as skin, blood vessels, and internal organs, especially in younger tissues. It consists of three identical α1 chains (encoded by the COL3A1 gene) forming a triple helix structure, coexisting with type I collagen to form a network structure. It is commonly found in the dermis of the skin, blood vessel walls, intestines, uterus, and other tissues that require elasticity.

[0003] Due to its high technical and cost barriers, recombinant collagen has been on the market for a relatively short time. However, compared to natural collagen, recombinant collagen has a molecular weight close to that of natural collagen, good water solubility, and features good penetration and high activity of large molecules. In particular, recombinant type III humanized collagen has strong healing and repair capabilities, which can enhance the skin's own repair ability, and is therefore more favored by the industry.

[0004] Recombinant collagen is obtained by introducing collagen genes from humans or other species into microorganisms (such as E. coli and yeast) or mammalian cells through gene recombination technology, followed by purification. Its amino acid sequence can be customized, avoiding the defects of animal-derived collagen. In the prior art, CN119431559A discloses a purification method for recombinant collagen. This patent obtains purified collagen through affinity chromatography combined with anion exchange, a method not yet available on the market. However, this purification method has limitations. It requires the development of specific affinity fillers for the specific protein; otherwise, the experiment cannot be completed. The process is complex, thus limiting its application. CN119431608A discloses a recombinant human type III collagen and its preparation method and application. It uses nickel affinity chromatography for purification. However, nickel affinity fillers have a short lifespan, are expensive, have complex regeneration steps, and cannot obtain high-purity collagen, failing to meet the raw material standards for medical devices and pharmaceuticals, greatly limiting the application of recombinant collagen. CN119613532A discloses a recombinant type III humanized collagen and its preparation method and uses. The purification process includes steps such as removing impurities, centrifugation, hollow fiber membrane clarification, ultrafiltration membrane concentration, and ion exchange. These steps are cumbersome and not conducive to production operations.

[0005] Therefore, developing a purification method that is simple, low-cost, easy to scale up, and can obtain high-purity collagen remains a pressing technical problem to be solved in this field. Summary of the Invention

[0006] In view of the shortcomings of the existing technology, the present invention provides a purification method for recombinant human type III collagen, which partially solves the technical problems mentioned in the background technology, such as the limitation of purification methods, the complexity of steps, and the inability to obtain high-purity collagen.

[0007] To achieve the above objectives, the present invention provides the following technical solution:

[0008] A method for purifying recombinant human type III collagen, wherein the amino acid sequence of the recombinant human type III collagen is shown in SEQ ID NO:1, and the method includes the following steps:

[0009] (1) Sample processing: obtain fermentation supernatant containing recombinant human type III collagen;

[0010] (2) Primary purification: After equilibrating the heparin affinity chromatography column with equilibration buffer, the fermentation supernatant obtained in step (1) is loaded onto the heparin affinity chromatography column and eluted with elution buffer containing NaCl. The primary purified eluted protein is collected.

[0011] (3) Advanced purification: The primary purified eluted protein obtained in step (2) is diluted with equilibration buffer and loaded onto a cation exchange column. After rinsing with washing buffer, it is eluted with elution buffer containing NaCl and the advanced purified eluted protein is collected.

[0012] (4) Ultrafiltration dialysis: The highly purified eluted protein obtained in step (3) is subjected to ultrafiltration dialysis to obtain recombinant human type III collagen stock solution.

[0013] In a preferred embodiment, the equilibration buffer of the heparin affinity chromatography column in step (2) is a buffer solution containing 10-30 mM Tris / Tris-HCl and 10-30 mM NaCl, with a pH of 7.2±0.1; the elution buffer is a buffer solution containing 10-30 mM Tris / Tris-HCl and 300-380 mM NaCl, with a pH of 7.2±0.1.

[0014] In a further preferred embodiment, the equilibration solution in step (2) contains 20 mM Tris / Tris-HCl and 20 mM NaCl, pH 7.2; the eluent contains 20 mM Tris / Tris-HCl and 340 mM NaCl, pH 7.2.

[0015] In a preferred embodiment, the equilibration buffer of the cation exchange column in step (3) is a buffer containing 40-60 mM NaAC / HAC, pH 5.5±0.1; the washing buffer is a buffer containing 40-60 mM NaAC / HAC and 80-120 mM NaCl, pH 5.5±0.1; and the elution buffer is a buffer containing 40-60 mM NaAC / HAC and 200-300 mM NaCl, pH 5.5±0.1.

[0016] In a further preferred embodiment, the equilibration solution in step (3) contains 50 mM NaAC / HAC and has a pH of 5.5; the rinsing solution contains 50 mM NaAC / HAC and 100 mM NaCl and has a pH of 5.5; and the eluent contains 50 mM NaAC / HAC and 260 mM NaCl and has a pH of 5.5.

[0017] In a preferred embodiment, in step (3), the primary purified eluted protein is diluted more than 10 times with equilibration buffer.

[0018] In a preferred embodiment, the dialysate used in step (4) is a buffer solution containing 15-25 mM His / His-HCl, pH 6.0±0.1, and the dialysis membrane pore size is 50 kDa.

[0019] In a preferred embodiment, the recombinant human type III collagen has a molecular weight of 45 kDa and an isoelectric point of 6.0.

[0020] In a further preferred embodiment, the fermentation supernatant in step (1) is derived from a Pichia pastoris expression system, and the recombinant human type III collagen has a hydroxylated modified triple helix structure.

[0021] The amino acid sequence of the recombinant human type III collagen described in this invention is shown in SEQ ID NO:1, and this sequence has the following characteristics:

[0022] (1) The sequence consists of 8 highly conserved repeating units, each containing about 36 amino acids, and the repeating units are highly homologous.

[0023] (2) The sequence is rich in basic amino acids, especially arginine (Arg, R) and lysine (Lys, K), which appear in a specific pattern in each repeating unit, forming a regular cluster of basic amino acids;

[0024] (3) This regular distribution of basic amino acid clusters makes multiple positively charged dense regions form on the surface of the collagen molecule, which can be electrostatically adsorbed at multiple sites with the heparin polysaccharide chain with strong negative charge, thereby achieving efficient specific affinity binding without the need to add any exogenous affinity tags.

[0025] (4) The theoretical isoelectric point of this collagen is about 6.0. It is positively charged at pH 5.5 and can be stably bound to the cation exchange medium. At this pH, most host protein impurities are negatively charged or do not bind, thus achieving efficient impurity removal.

[0026] (5) The collagen prepared by the method described in the Chinese patent application filed on the same day, entitled “Pichia pastoris staged double-induced expression of hydroxylated recombinant humanized collagen and its preparation method and application”, has a high degree of hydroxylation of 13.7% hydroxyproline and has formed a stable triple helix structure as confirmed by circular dichroism chromatography. This complete higher-order structure further enhances its specificity in interacting with the chromatographic medium.

[0027] The aforementioned sequence and structural features together determine that the recombinant human type III collagen described in this invention has a unique natural affinity for heparin affinity mediators and cation exchange mediators, providing a structural basis for the simple and efficient purification process design of this invention.

[0028] The beneficial effects of this invention are:

[0029] Compared with the prior art, the present invention has the following beneficial effects:

[0030] (1) Highly targeted and simplified process: This invention targets recombinant human type III collagen with a specific sequence characteristic (SEQ ID NO:1). Utilizing its naturally rich basic amino acid sequence, it directly employs heparin affinity chromatography for primary capture. This collagen has a natural affinity for heparin, requiring no additional affinity tags. The fermentation broth can be directly loaded after centrifugation without dialysis or concentration steps, solving the problem of excessively large sample volume due to dilution, thus significantly simplifying the process.

[0031] (2) Two-step chromatography for high purity: A two-step purification strategy of "heparin affinity chromatography + cation chromatography" is adopted to make full use of the charge distribution and isoelectric point characteristics of the target collagen to achieve efficient separation and purification. The purity of the obtained collagen stock solution can reach more than 99%, and the endotoxin content is less than 5 EU / mg, which fully meets the Class III medical device injection grade raw material standards.

[0032] (3) The packing material is universal and the cost is low: the cation exchange packing material is a commercially available universal packing material, and the price is lower than that of nickel affinity packing material. Compared with nickel affinity packing material, heparin affinity packing material reduces the steps of adding and enzymatically cleaving His tags, making the process simpler and more convenient. In addition, the column chromatography method facilitates the recovery and recycling of the packing material, which greatly reduces the cost of industrial production.

[0033] (4) Easy to scale up and robust process: The method of this invention has simple steps, clear parameters for each step, is not limited by scale, can be freely scaled up to different production scales, has a short production cycle, high batch consistency, and is suitable for large-scale industrial production.

[0034] (5) Upstream and downstream collaboration to form a complete technology chain: This invention and the Pichia pastoris expression method applied for on the same day form a complete technology chain. The upstream provides high-quality hydroxylated collagen raw materials, and the downstream obtains medical-grade products through adaptive purification processes. Together, they have built a complete technology barrier from the construction of genetically engineered bacteria to high-purity collagen products. Attached Figure Description

[0035] Figure 1 This is a flowchart illustrating the purification process of recombinant human type III collagen in an embodiment of the present invention.

[0036] Figure 2 This is a flowchart of the primary purification process in an embodiment of the present invention;

[0037] Figure 3 This is a flowchart of the advanced purification process in an embodiment of the present invention;

[0038] Figure 4 This is the primary purification chromatography pattern in Example 1 of the present invention;

[0039] Figure 5 This is the advanced purification chromatography pattern in Example 1 of the present invention;

[0040] Figure 6 This is the electrophoretic detection pattern of the protein sample in Example 1 of the present invention;

[0041] Figure 7 This is the circular dichroism spectrum of the protein sample in Example 1 of the present invention. Detailed Implementation

[0042] The technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0043] Unless otherwise specified, the experimental methods used in the following examples are conventional methods.

[0044] Unless otherwise specified, all materials and reagents used in the following examples are commercially available.

[0045] The recombinant human type III collagen used in the following examples has the amino acid sequence shown in SEQ ID NO:1, and was prepared by the method described in the Chinese patent application filed by the inventors on the same day, entitled "Pichia pastoris staged double-induced expression of hydroxylated recombinant human collagen and its preparation method and application". The collagen was found to have a hydroxyproline content of 13.7%, and circular dichroism spectroscopy analysis showed a negative peak at 195 nm and a positive peak at 220 nm, exhibiting typical triple helix structure characteristics of collagen. The fermentation supernatant was directly used for the purification experiments described below after centrifugation.

[0046] The amino acid sequence shown in SEQ ID NO:1 is as follows:

[0047] GHPERGEAGIPGVPGSPQAGAPKGEPGPRGGPVGPAYQGPPGEPGGGSPGSPGAPGAPGHPGPGHPERGEAGIPGVPGSPQAGAPKGEPGPRGGPVGPAYQGPPGEPGGGSPGSPGAPGAPGHPGP GHPERGEAGIPGVPGSPQAGAPKGEPGPRGGPVGPAYQGPPGEPGGGSPGSPGAPGAPGHPGPGHPERGEAGIPGVPGSPQAGAPKGEPGPRGGPVGPAYQGPPGEPGGGSPGSPGAPGAPGHPGP GHPERGEAGIPGVPGSPQAGAPKGEPGPRGGPVGPAYQGPPGEPGGGSPGSPGAPGAPGHPGPGHPERGEAGIPGVPGSPQAGAPKGEPGPRGGPVGPAYQGPPGEPGGGSPGSPGAPGAPGHPGP GHPERGEAGIPGVPGSPQAGAPKGEPGPRGGPVGPAYQGPPGEPGGGSPGSPGAPGAPGHPGPGHPERGEAGIPGVPGSPQAGAPKGEPGPRGGPVGPAYQGPPGEPGGGSPGSPGAPGAPGHPGP

[0048] The recombinant human type III collagen has a molecular weight of approximately 45 kD and an isoelectric point of approximately 6.

[0049] Example 1

[0050] A method for purifying recombinant human type III collagen, comprising the following steps:

[0051] (1) Sample processing: After centrifuging the cultured fermentation broth at 6000 r / min for 15 min, the supernatant was collected and filtered through a 0.22 μm filter membrane;

[0052] (2) Primary purification: Heparin affinity chromatography column packing specifications: column bed volume 32 mL, column inner diameter 15 mm, column height 18 cm;

[0053] Chromatography medium: Heparin Beads 6FF;

[0054] Equilibration buffer HA: composed of 20 mM Tris / Tris-HCl, 20 mM NaCl and water, pH 7.2;

[0055] Elution buffer HB: composed of 20 mM Tris / Tris-HCl, 340 mM NaCl and water, pH 7.2;

[0056] The specific steps are as follows:

[0057] (2-1) Column equilibration: Connect the primary purification equilibration buffer to port A1 of pump A, and equilibrate the heparin affinity chromatography column with the primary purification equilibration buffer HA at a flow rate of 100 cm / h, equilibrate 3 CV;

[0058] (2-2) Sample loading: Connect the sample to port A2 of pump A, and load the fermentation supernatant obtained in step (1) onto the column after treatment in (2-1). The packing material loading is about 20 mg / mL and the flow rate is 100 cm / h.

[0059] (2-3) Column equilibration: Connect the primary purification equilibration buffer to port A1 of pump A, and equilibrate the heparin affinity chromatography column with the primary purification equilibration buffer HA at a flow rate of 100 cm / h, equilibrate 3 CV;

[0060] (2-4) Elution: Connect the primary purification eluent HB to port B1 of pump B. Wash the chromatography column with the primary purification eluent at a flow rate of 100 cm / h. Start collecting when the UV detection peak reaches 50 mAU and stop collecting when the detection peak drops back to 50 mAU. The elution volume is 5 CV.

[0061] The purity of the eluent sample was determined by SDS-PAGE electrophoresis. The primary purification chromatogram is shown below. Figure 4 In the figure, P1 represents the primary purification elution peak; the electrophoresis detection pattern is shown below. Figure 6In the figure, lane 1 shows the electrophoretic bands of the protein before primary purification, and lane 2 shows the electrophoretic bands of the protein after primary purification. The purity of the eluted sample in this step is approximately 80%, the collection volume is 55 mL, and the endotoxin test result is 236.1 EU / mg (endotoxin detection method is performed according to the gel limit method of the Chinese Pharmacopoeia (2025 edition)).

[0062] (3) Advanced purification: Cation chromatography column packing specifications: column bed volume 32 mL, column inner diameter 15 mm, column height 18 cm;

[0063] Chromatography medium: SP SEPHAROSE FF;

[0064] Equilibration buffer SA: composed of 50 mM NaAC / HAC and water, pH 5.5;

[0065] Rinse buffer SB: composed of 50 mM NaAC / HAC, 100 mM NaCl and water, pH 5.5;

[0066] Elution buffer SC: composed of 50 mM NaAC / HAC, 260 mM NaCl and water, pH 5.5;

[0067] The specific steps are as follows:

[0068] (3-1) Column equilibration: Connect the advanced purification equilibration solution to port A1 of pump A, and equilibrate the cation exchange column with advanced purification equilibration solution SA at a flow rate of 100 cm / h for 3 CV.

[0069] (3-2) Sample loading: Add 40 mL of the eluted protein after primary purification to the advanced purification equilibration buffer and bring the volume to 400 mL. This protein is used as the sample loading protein. Connect the sample to port A2 of pump A and load the sample onto the column treated in (3-1) at a flow rate of 100 cm / h. The packing material loading is approximately 11.2 mg / mL.

[0070] (3-3) Column equilibration: Connect the advanced purification equilibration solution to port A1 of pump A, and equilibrate the cation exchange column with advanced purification equilibration solution SA at a flow rate of 100 cm / h for 3 CV.

[0071] (3-4) Column washing: Connect the high-purification washing buffer to port B1 of pump B, and wash the cation exchange column with high-purification washing buffer SB at a flow rate of 100 cm / h, and equilibrate to 5 CV;

[0072] (3-5) Elution: Connect the high-purification eluent to port B2 of pump B, and elute with high-purification eluent SC at a flow rate of 100 cm / h. Start collecting when the UV detection peak reaches 50 mAU and stop collecting when the detection peak drops back to 50 mAU. The elution volume is 10 CV.

[0073] The high-purification chromatography chromatogram of the eluent sample is shown below. Figure 5 In the figure, P2 is the elution peak of advanced purification; the electrophoretic detection pattern is shown in [reference needed]. Figure 6 The third lane in the figure shows the electrophoresis bands for highly purified proteins. The purity of the eluted sample in this step was approximately 99.0%, the collection volume was 234 mL, and the endotoxin test result was 3.41 EU / mg.

[0074] (4) Ultrafiltration dialysis: Dialysis buffer: composed of water with a final concentration of 20 mM His / His-HCl, pH 6.0;

[0075] The hollow fiber used in the dialysis is a commercially available brand with a pore size of 50 kDa;

[0076] The inlet pressure used for dialysis is 0.1 MPa;

[0077] The dialysis volume is 8 times the sample volume;

[0078] The specific steps are as follows:

[0079] (4-1) Prepare 200 mL of highly purified eluted protein;

[0080] (4-2) Prepare dialysis buffer;

[0081] (4-3) Prepare and assemble hollow fiber columns;

[0082] (4-4) Begin concentration by passing the protein through a hollow fiber column to concentrate it to 100 mL;

[0083] (4-5) Perform dialysis using conventional methods until dialysis is completed;

[0084] (4-6) After dialysis, adjust the protein concentration to the target level.

[0085] The purity of the original protein was determined by SDS-PAGE electrophoresis. The electrophoretic pattern is shown below. Figure 6 The fourth lane in the figure shows the protein electrophoresis bands after ultrafiltration dialysis. The purity of the finished sample in this step is approximately 99.2%, and the endotoxin test result is 2.58 EU / mg.

[0086] Circular dichroism spectroscopy revealed that this collagen has a triple helix structure, see details below. Figure 7 .

[0087] Example 2

[0088] This embodiment discloses a purification method for recombinant human type III collagen, including the following steps:

[0089] (1) Sample preparation:

[0090] The sample processing steps are the same as in Example 1;

[0091] (2) Primary purification:

[0092] Heparin affinity chromatography column packing specifications: column bed volume 53 mL, column inner diameter 15 mm, column height 30 cm;

[0093] Chromatography medium: Heparin Beads 6FF;

[0094] Equilibration buffer HA: composed of 20 mM Tris / Tris-HCl, 19 mM NaCl and water, pH 7.2;

[0095] Elution buffer HB: composed of 20 mM Tris / Tris-HCl, 360 mM NaCl and water, pH 7.2;

[0096] The specific steps are as follows:

[0097] (2-1) Column equilibration: Connect the primary purification equilibration buffer to port A1 of pump A, and equilibrate the heparin affinity chromatography column with the primary purification equilibration buffer HA at a flow rate of 100 cm / h, equilibrate 3 CV;

[0098] (2-2) Sample loading: Connect the sample to port A2 of pump A, and load the fermentation supernatant obtained in step (1) onto the column after treatment in (2-1). The packing material loading is about 23 mg / mL and the flow rate is 100 cm / h.

[0099] (2-3) Column equilibration: Connect the primary purification equilibration buffer to port A1 of pump A, and equilibrate the heparin affinity chromatography column with the primary purification equilibration buffer HA at a flow rate of 100 cm / h, equilibrate 3 CV;

[0100] (2-4) Elution: Connect the primary purification eluent to port B1 of pump B. Wash the chromatography column with the primary purification eluent at a flow rate of 100 cm / h. Start collecting when the UV detection peak reaches 50 mAU and stop collecting when the detection peak drops back to 50 mAU. The elution volume is 5 CV.

[0101] The purity of the eluted sample was approximately 75%, the collection volume was 86 mL, and the endotoxin test result was 147.09 EU / mg.

[0102] (3) Advanced purification:

[0103] Cation chromatography column packing specifications: column bed volume 18 mL, column inner diameter 15 mm, column height 10 cm;

[0104] Chromatography medium: SP SEPHAROSE FF;

[0105] Equilibration buffer SA: composed of 50 mM NaAC / HAC and water, pH 5.5;

[0106] Rinse buffer SB: composed of 50 mM NaAC / HAC, 120 mM NaCl and water, pH 5.5;

[0107] Elution buffer SC: composed of 50 mM NaAC / HAC, 300 mM NaCl and water, pH 5.5;

[0108] The specific steps are as follows:

[0109] (3-1) Column equilibration: Connect the advanced purification equilibration solution to port A1 of pump A, and equilibrate the cation exchange column with advanced purification equilibration solution SA at a flow rate of 100 cm / h for 3 CV.

[0110] (3-2) Sample loading: Add 25 mL of the eluted protein after primary purification to the advanced purification equilibration buffer and bring the volume to 250 mL. This protein is used as the sample loading protein. Connect the sample to port A2 of pump A and load the sample onto the column treated in (3-1) at a flow rate of 100 cm / h. The packing material loading is 14 mg / mL.

[0111] (3-3) Column equilibration: Connect the advanced purification equilibration solution to port A1 of pump A, and equilibrate the cation exchange column with advanced purification equilibration solution SA at a flow rate of 100 cm / h for 3 CV.

[0112] (3-4) Column washing: Connect the high-purification washing buffer to port B1 of pump B, and wash the cation exchange column with high-purification washing buffer SB at a flow rate of 100 cm / h, and equilibrate to 5 CV;

[0113] (3-5) Elution: Connect the high-purification eluent to port B2 of pump B, and elute with high-purification eluent SC at a flow rate of 100 cm / h. Start collecting when the UV detection peak reaches 50 mAU and stop collecting when the detection peak drops back to 50 mAU. The elution volume is 10 CV.

[0114] The purity of the eluted sample was approximately 99.5%, the collection volume was 152 mL, and the endotoxin test result was 7.13 EU / mg.

[0115] (4) Ultrafiltration dialysis:

[0116] The ultrafiltration dialysis procedure is the same as in Example 1;

[0117] The purity of the finished protein was determined by SDS-PAGE electrophoresis. The purity of the finished sample at this step was approximately 99.4%, and the endotoxin test result was 3.40 EU / mg.

[0118] Example 3

[0119] A method for purifying recombinant human type III collagen, comprising the following steps:

[0120] (1) Sample preparation:

[0121] The sample processing steps are the same as in Example 1;

[0122] (2) Primary purification:

[0123] Heparin affinity chromatography column packing specifications: column bed volume 18 mL, column inner diameter 15 mm, column height 10 cm;

[0124] Chromatography medium: Heparin Beads 6FF;

[0125] Equilibration buffer HA: composed of 20 mM Tris / Tris-HCl, 22 mM NaCl and water, pH 7.2;

[0126] Elution buffer HB: composed of 20 mM Tris / Tris-HCl, 320 mM NaCl and water, pH 7.2;

[0127] The specific steps are as follows:

[0128] (2-1) Column equilibration: Connect the primary purification equilibration buffer to port A1 of pump A, and equilibrate the heparin affinity chromatography column with the primary purification equilibration buffer HA at a flow rate of 100 cm / h, equilibrate 3 CV;

[0129] (2-2) Sample loading: Connect the sample to port A2 of pump A, and load the fermentation supernatant obtained in step (1) onto the column after treatment in (2-1). The packing material loading is 24 mg / mL and the flow rate is 100 cm / h.

[0130] (2-3) Column equilibration: Connect the primary purification equilibration buffer to port A1 of pump A, and equilibrate the heparin affinity chromatography column with the primary purification equilibration buffer at a flow rate of 100 cm / h, equilibrate 3 CV;

[0131] (2-4) Elution: Connect the primary purification eluent to port B1 of pump B. Wash the chromatography column with the primary purification eluent at a flow rate of 100 cm / h. Start collecting when the UV detection peak reaches 50 mAU and stop collecting when the detection peak drops back to 50 mAU. The elution volume is 5 CV.

[0132] The purity of the eluted sample was approximately 78%, the collection volume was 30 mL, and the endotoxin test result was 325.84 EU / mg.

[0133] (3) Advanced purification:

[0134] Cation chromatography column packing specifications: column bed volume 53 mL, column inner diameter 15 mm, column height 30 cm;

[0135] Chromatography medium: SP SEPHAROSE FF;

[0136] Equilibration buffer SA: composed of 50 mM NaAC / HAC and water, pH 5.5;

[0137] Rinse buffer SB: composed of 50 mM NaAC / HAC, 80 mM NaCl and water, pH 5.5;

[0138] Elution buffer SC: composed of 50 mM NaAC / HAC, 210 mM NaCl and water, pH 5.5;

[0139] The specific steps are as follows:

[0140] (3-1) Column equilibration: Connect the advanced purification equilibration solution to port A1 of pump A, and equilibrate the cation exchange column with advanced purification equilibration solution SA at a flow rate of 100 cm / h for 3 CV.

[0141] (3-2) Sample loading: Add 60 mL of the eluted protein after primary purification to the advanced purification equilibration buffer and bring the volume to 600 mL. This protein is used as the sample loading protein. Connect the sample to port A2 of pump A and load the sample onto the column treated in (3-1) at a flow rate of 100 cm / h. The packing material loading is 11 mg / mL.

[0142] (3-3) Column equilibration: Connect the advanced purification equilibration solution to port A1 of pump A, and equilibrate the cation exchange column with advanced purification equilibration solution SA at a flow rate of 100 cm / h for 3 CV.

[0143] (3-4) Column washing: Connect the high-purification washing buffer to port B1 of pump B, and wash the cation exchange column with high-purification washing buffer SB at a flow rate of 100 cm / h, and equilibrate to 5 CV;

[0144] (3-5) Elution: Connect the high-purification eluent to port B2 of pump B, and elute with high-purification eluent SC at a flow rate of 100 cm / h. Start collecting when the UV detection peak reaches 50 mAU and stop collecting when the detection peak drops back to 50 mAU. The elution volume is 10 CV.

[0145] The purity of the eluted sample was approximately 99.7%, the collection volume was 439 mL, and the endotoxin test result was 2.68 EU / mg.

[0146] (4) Ultrafiltration dialysis:

[0147] The ultrafiltration dialysis procedure is the same as in Example 1;

[0148] The purity of the finished protein was determined by SDS-PAGE electrophoresis. The purity of the finished sample at this step was approximately 99.8%, and the endotoxin test result was 1.65 EU / mg.

[0149] Comparative Example 1

[0150] The difference from Example 1 is that in the primary purification process of step (2), a hydrophobic chromatography column is used instead of a heparin affinity chromatography column, and the packing specifications of the chromatography column are the same as those in Example 1.

[0151] Comparative Example 2

[0152] The difference from Example 1 is that in step (2) of the primary purification process:

[0153] Equilibrium solution (HA): composed of 20 mM Tris / Tris-HCl, 20 mM KCl and water, pH 7.2;

[0154] Eluent (HB): Composed of 20 mM Tris / Tris-HCl, 340 mM KCl and water, pH 7.2.

[0155] Comparative Example 3

[0156] The difference from Example 1 is that the NaCl in the eluent (HB) used in the primary purification process of step (2) is 280 mM.

[0157] Comparative Example 4

[0158] The difference from Example 1 is that the NaCl in the eluent (HB) used in the primary purification process of step (2) is 400mM.

[0159] Comparative Example 5

[0160] The difference from Example 1 is that in the advanced purification process of step (3), a cationic composite chromatography column is used instead of a cationic chromatography column, and the packing specifications of the chromatography column are the same as those in Example 1.

[0161] Comparative Example 6

[0162] The difference from Example 1 is that in step (3) of the advanced purification process:

[0163] Equilibration buffer SA: composed of 50 mM NaAC / HAC and water, pH 5.5;

[0164] Rinse buffer SB: composed of 50 mM NaAC / HAC, 100 mM KCl and water, pH 5.5;

[0165] Elution buffer SC: composed of 50 mM NaAC / HAC, 260 mM KCl and water, pH 5.5.

[0166] Test Example 1

[0167] The purified collagen products obtained in Examples 1-3 and Comparative Examples 1-6 were tested, including yield, concentration, purity, and endotoxin content. The test results are shown in Table 1.

[0168] Table 1. Detection data of collagen liquid in the examples and comparative examples.

[0169] Yield (%) Concentration (mg / mL) purity(%) Endotoxin (EU / mg) Example 1 55 3.52 99.2 2.58 Example 2 65 3.49 99.4 3.40 Example 3 62 2.96 99.8 1.65 Comparative Example 1 18 1.12 58.8 397.23 Comparative Example 2 49 2.54 95.1 123.17 Comparative Example 3 43 2.16 85.1 56.12 Comparative Example 4 59 4.65 78.4 276.97 Comparative Example 5 N / A N / A N / A N / A Comparative Example 6 42 1.69 75.37 127.74

[0170] The test data above show that the finished collagen stock solution obtained through Examples 1 to 3 has a purity of over 99%, a yield of over 50%, and the endotoxin results meet the quality requirements.

[0171] Comparative Example 1 replaced the primary purification heparin affinity chromatography column with hydrophobic chromatography. Hydrophobic chromatography is a chromatographic method that separates sample components by utilizing the difference in hydrophobic forces between the hydrophobic groups of the sample components and the hydrophobic ligands of the stationary phase in a salt-water system. The recombinant collagen in this invention has strong hydrophilicity and weak hydrophobicity, resulting in weak binding ability to the hydrophobic chromatography packing material. Experimental results showed that the yield became very low after hydrophobic chromatography, with a purity of 58.8%, far below the quality requirements and failing to achieve the purification objective.

[0172] Comparative Examples 2 and 6 replaced the purified sodium chloride system with the potassium chloride system. There are key differences between the two systems, which need to be selected in specific experiments. The experimental results show that the sodium chloride system is far superior to the potassium chloride system. Furthermore, K⁺ inhibits the activity of some enzymes, while Na⁺ is the main cation at physiological concentrations, is gentler on most biomolecules, and is also less expensive.

[0173] In Comparative Example 3, the concentration of NaCl was too low, resulting in lower conductivity and incomplete elution of the protein. This led to a higher proportion of protein degradation fragments being eluted, resulting in lower yield and concentration, as well as a corresponding decrease in purity.

[0174] In Comparative Example 4, the NaCl concentration was too high, resulting in higher elution conductivity. Some polymers were eluted simultaneously, leading to poorer protein purity and worse endotoxin results.

[0175] Comparative Example 5 replaced the advanced purification cation exchange column with a cation-composite chromatography column. Cation-composite chromatography integrates traditional cation exchange groups and additional affinity or hydrophobic groups on a single chromatographic medium. Through the synergistic effect of electrostatic and non-electrostatic interactions (such as hydrophobicity, metal chelation, and hydrogen bonding), it achieves the purification of target molecules. During the experiment, the protein bound to the packing material could not be eluted, resulting in a very low loading capacity. The protein completely disappeared during elution, failing to achieve the purification objective and losing its purification effect.

[0176] The purification method for recombinant human type III collagen disclosed in this invention is simple, as follows: Figure 1-3 As shown, the purity of the obtained collagen stock solution can reach over 99%, which greatly reduces the cost of industrial production. The column chromatography technology used in particular facilitates the recovery and recycling of the packing material, making it more suitable for large-scale production. It also has good purification effect and can produce collagen products that meet the requirements of Class III medical devices, thus having extremely high industrial application value.

Claims

1. A method for purifying recombinant human type III collagen, characterized in that, The amino acid sequence of the recombinant human type III collagen is shown in SEQ ID NO:1, and the method includes the following steps: (1) Sample processing: obtain fermentation supernatant containing recombinant human type III collagen; (2) Primary purification: After equilibrating the heparin affinity chromatography column with equilibration buffer, the fermentation supernatant obtained in step (1) is loaded onto the heparin affinity chromatography column and eluted with elution buffer containing NaCl. The eluted protein is collected after primary purification. The equilibration buffer of the heparin affinity chromatography column is a buffer containing 10-30 mM Tris / Tris-HCl and 10-30 mM NaCl, pH 7.2±0.1; the elution buffer is a buffer containing 10-30 mM Tris / Tris-HCl and 300-380 mM NaCl, pH 7.2±0.

1. (3) Advanced purification: The primary purified eluted protein obtained in step (2) is diluted more than 10 times with equilibration buffer and then loaded onto a cation exchange column. After rinsing with washing buffer, it is eluted with elution buffer containing NaCl, and the advanced purified eluted protein is collected. The equilibration buffer of the cation exchange column is a buffer containing 40-60 mM NaAC / HAC, pH 5.5±0.1; the washing buffer is a buffer containing 40-60 mM NaAC / HAC and 80-120 mM NaCl, pH 5.5±0.1; the elution buffer is a buffer containing 40-60 mM NaAC / HAC and 200-300 mM NaCl, pH 5.5±0.

1. (4) Ultrafiltration dialysis: The highly purified eluted protein obtained in step (3) is subjected to ultrafiltration dialysis to obtain recombinant human type III collagen stock solution; the dialysis solution used in the ultrafiltration dialysis is a buffer solution containing 15-25 mM His / His-HCl, pH 6.0±0.1, and the dialysis membrane pore size is 50 kDa.

2. The purification method for recombinant human type III collagen as described in claim 1, characterized in that, The equilibration solution in step (2) contains 20 mM Tris / Tris-HCl and 20 mM NaCl, pH 7.2; the eluent contains 20 mM Tris / Tris-HCl and 340 mM NaCl, pH 7.

2.

3. The purification method for recombinant human type III collagen as described in claim 1, characterized in that, The equilibration solution in step (3) contains 50 mM NaAC / HAC and has a pH of 5.5; the rinsing solution contains 50 mM NaAC / HAC and 100 mM NaCl and has a pH of 5.5; and the elution solution contains 50 mM NaAC / HAC and 260 mM NaCl and has a pH of 5.

5.

4. The purification method for recombinant human type III collagen as described in claim 1, characterized in that, The recombinant human type III collagen has a molecular weight of 45 kDa and an isoelectric point of 6.

0.

5. The purification method for recombinant human type III collagen as described in any one of claims 1-4, characterized in that, The fermentation supernatant in step (1) is derived from the Pichia pastoris expression system, and the recombinant human type III collagen has a hydroxylated modified triple helix structure.

6. A recombinant human type III collagen stock solution, characterized in that, It is prepared by the purification method of recombinant human type III collagen according to any one of claims 1-5, and has a purity ≥99% and an endotoxin content ≤5 EU / mg.

Citation Information

Patent Citations

  • Recombinant human-derived III-type collagen as well as preparation method and application thereof

    CN119431608A

  • Recombinant III-type humanized collagen as well as preparation method and application thereof

    CN119613532A

  • Wound care product comprising ECM-functionalized nanocellulose

    EP3181153A1

  • A recombinant collagen protein and its use in cartilage repair matrix

    US20240115763A1